Otsuka's first-half pharma sales constrained by currency effects
This article was originally published in Scrip
Otsuka Holdings has released its first financial results under the disclosure requirements that it is now governed by as a listed company. The Japanese group floated on the Tokyo Stock Exchange on 15 December, raising around $2.4 billion.
You may also be interested in...
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.